Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Manic Disorder Clear all
Completed Phase 2 Interventional

Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

NCT00854737
View directory record Official record
Conditions
Bipolar Disorder
Interventions
cytidine, omega-3 fatty acids, placebo
Dietary Supplement · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Belmont, Massachusetts • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder

NCT00257972
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional Results available

Inositol and Omega-3 Fatty Acids in Pediatric Mania

NCT01396486
View directory record Official record
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
Omega-3, Inositol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 30, 2026, 7:12 AM EDT
Terminated Phase 4 Interventional Results available

Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

NCT00592358
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
paliperidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

NCT00393978
View directory record Official record
Conditions
Bipolar Disorder, Cannabis-Related Disorder
Interventions
Quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 30, 2026, 7:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Effects On Mood Symptoms in Bipolar Disorder

NCT00472615
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00139594
View directory record Official record
Conditions
Bipolar Disorder
Interventions
licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
La Palma, California • Kansas City, Kansas • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 30, 2026, 7:12 AM EDT
Terminated Phase 4 Interventional

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
15
States / cities
Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181727
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

NCT00550394
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Abuse
Interventions
quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional

Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

NCT00181922
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
ziprasidone (Geodon)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

NCT00596622
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium
Drug
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

NCT00257166
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone oral capsules, placebo oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
50
States / cities
Scottsdale, Arizona • Orange, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional

Aripiprazole in Patients With Acute Mania

NCT00095511
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 1 Interventional

Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?

NCT02081287
View directory record Official record
Conditions
Bipolar Disorder, Manic Depression
Interventions
IP6, Lamotrigine
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine for Mania

NCT01058096
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Long Beach, California • Riverside, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

NCT01059539
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Springdale, Arkansas • Carson, California • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

NCT00422214
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Not applicable Interventional Results available

Examining the Effect of EEG-guided Theta Burst Stimulation in Bipolar Disorder

NCT05179785
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Continuous Theta Burst Stimulation (cTBS), Intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Mary Phillips, MD MD (Cantab)
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 7:12 AM EDT
Completed Phase 2 Interventional

Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness

NCT00015769
View directory record Official record
Conditions
Bipolar Disorder
Interventions
levetiracetam
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 7:12 AM EDT